Clinical trial · Observational
Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer
Clinical Outcomes of ER-Positive to Negative Conversion Versus Triple-Negative Breast Cancer (TNBC): Evidence From a 18F-fluoroestradiol Positron Emission Tomography/Computed Tomography (18F-FES PET/CT) Guided Propensity-Score-Matched Study
NCT07316439CI-TRIAL-00100123active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to compare survival outcomes and clinical characteristics between ER loss and metastatic triple-negative breast cancer (mTNBC) patients, exploring the prognostic implications of dynamic ER changes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- ER negative conversion group
- description
- 82 patients with functional ER loss detected by FES-PET at metastatic sites before first-line treatment
- label
- mTNBC
- description
- A total of 115 contemporaneous patients with metastatic TNBC at initial diagnosis
Primary outcomes (1)
- measure
- Progression-Free Survival
- timeFrame
- 6 weeks
Secondary outcomes (2)
- measure
- Overall Response Rate
- timeFrame
- 6 weeks
- measure
- Disease Control Rate
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage. * MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2017 and 2023 * Patients diagnosed with primary ER-positive tumor and who were yet to receive any systemic therapy during the advanced stage * Contemporaneous patients with metastatic TNBC at initial diagnosis Exclusion Criteria: * Patients with incomplete medical records and those diagnosed with secondary primary tumors
References
Publications (0)
Data not yet available
No reference posted for this study.